cyrilzakka/clinical-trials huggingface dataset:
A Case Series on Incidentally Detected Gallbladder Malignancy

A retrospective analysis of data, using the Hospital records of all the patients who underwent cholecystectomy for benign conditions at Osmania General Hospital in a year (2019).

A retrospective analysis of hospital records of patients who underwent Cholecystectomy in a year duration (2019) for any benign condition, diagnosed and confirmed histopathologically as Gallbladder Malignancy.

There are a total of one hundred and eighty patients who underwent cholecystectomy at our hospital (Osmania General Hospital) in 2019, out of which seven patients' histopathological diagnosis was gall bladder malignancy. We reviewed all the case's history, cross-checked the histopathological slides, and confirmed the diagnosis. To avoid the bias of covid-19 pandemic in surgical practice we confined the patient records to the pre-pandemic period of one-year duration (2019).

A total of 180 patients underwent cholecystectomy for various benign conditions in one year, out of which seven patients confirmed histopathologically with Gallbladder malignancy.

Total no of patients : 180 Diagnosed with malignancy : 7 percentage 3.8%

Among these seven, three patients converted from laparoscopic to open procedure for difficulty with resection, two patients are posted for surgery considering empyema of gall bladder preoperatively, one patient in view of gall bladder perforation, and for two patients preoperative diagnosis was gall bladder polyp.

Converted from Lap to Open: 3 Pre-op GB Polyp : 2 Perforated GB : 1 Empyema GB : 2

Only one patient is 40 years old and others are more than 50 years, and two of them are males.

Total : 7 100% Males : 2 28.5% Females : 5 71.5%

Out of a total of 180 patients who underwent cholecystectomy, 117 are females and 63 are males

Total : 180 Males : 63 Females : 117

Out of 180, the age distribution is as follows

Age. Percentage 20 - 29 0 30 - 39 0 40 - 49 0.005 \>50. 99.99

It implies that the malignancy rate increases with an increase in the patient's age more than 50years and also with gender (Females \> males).

Eligibility Criteria:
Inclusion Criteria: All patients who underwent cholecystectomy for benign conditions -

Exclusion Criteria: All those who already diagnosed with gallbladder malignancy

-
Assess the Effectiveness of Atomoxetine in Children With Fetal Alcohol Syndrome and ADD/ADHD

The purpose of this study is to determine if atomoxetine hydrochloride improves inattention, hyperactivity, and impulsivity problems in children exposed to alcohol during birth.

Abnormalities of attention, function, and activity level in children exposed to alcohol in utero share similarities and differences to children who do not have alcohol exposure. Previous psychological studies have examined either core attention deficit hyperactivity disorder (ADHD)symptoms of hyperactivity, inattention, and impulsivity or hypothesized neuropsychological differences in children with fetal alcohol syndrome (FAS) and ADHD. Atomoxetine Hydrochloride is a non-stimulant medication used to treat ADHD. This study will determine if atomoxetine HCL significantly reduces symptoms of ADD/ADHD in children with fetal alcohol exposure.

Eligibility Criteria:
Inclusion Criteria:

* Patient must be between the ages of 4 and 11 years at the time of entry into the study.
* Patients must meet diagnostic criteria for FASD
* Patient must meet DSM-IV criteria for ADHD, any subtype and must have an ADHDRS-IV score of \> or = to 90%ile for age and gender for either subtest or total score if greater than 5 years of age.
* Patients who enter the study at visit 1 taking stimulant medication must be medication-free for at least 24 hours before visit 2.
* History and physical exam must reveal no clinically significant abnormalities that would preclude safe participation in the study.
* Patients must be able to swallow capsules.
* Patients must be of a sufficient developmental level (\~3 yrs) to participate in the study.
* Patients and parents must be able to communicate effectively with the investigator and coordinator and be judged reliable to keep appointments and participate in data collection.
* Teacher must agree to cooperate with the study. Children less than 6 years old must have completed a course of PCIT and still meet DSM-IV criteria for ADHD.

Exclusion Criteria:

* Have received an in investigational medication in the past 30 days.
* Are currently on a medication treatment that is effective (ADHDRS-IV score within 1 SD of average) and well tolerated.
* Have significant current medical conditions that could be exacerbated or compromised by atomoxetine.
* Have used MAOIs within one month prior to visit 2.
* Patients with hypertension.
* Patients with a previous diagnosis of bipolar disorder, psychosis, or autism spectrum disorder.
* Patients taking anticonvulsants for seizure control.
* Patients taking another psychotropic medication or health food supplements purported to have central nervous system activity within 5 half-lives of visit 2.
* Patients with Tourette Disorder or any other neurological condition that would interfere with their ability to receive treatment or comply with monitoring.
* Pubertal girls.
Dysphagia and Dysphonia Outcomes in SARS CoV-2 (COVID-19) Infection (DYADS Study)

This study examines the presence, severity and natural history of dysphagia and dysphonia in the post-extubation and severely unwell COVID-19 patient.


Eligibility Criteria:
Inclusion Criteria:

* Patients who have been diagnosed with a positive SARS CoV-2 test.
* Patients who have been diagnosed with dysphonia and/or dysphagia following COVID 19 treatment.
* Patients who require investigation and management for dysphonia and/or dysphagia following COVID 19 treatment.
* Adult patients aged 18 years - 85 years.
* Patients that meet threshold for referral to the joint MDT clinic following screening

Exclusion Criteria:

* Patients who cannot undertake the assessment for dysphonia and/or dysphagia.
* Patients who are being managed with palliative intent.
* Patients with pre-existing dysphonia and/or dysphagia not previously responding to therapy (pre-existing prior to COVID-19 diagnosis).
Pilot of a Group-based Program on Lifestyle-integrated Functional Exercise (LiFE) in Older Persons

This feasibility pilot is part of the project "LiFE-is-LiFE" (2017-2020). It is based on the Lifestyle-Integrated Functional Exercise (LiFE) program by Clemson et al., which has proven effective in improving strength, balance, and physical activity while simultaneously reducing falls in older people via incorporating exercises in recurring daily tasks. However, implementing the original LiFE program includes high financial requirements and human resources. Therefore, LiFE-is-LiFE investigates whether implementing LiFE in groups (gLiFE) is not inferior to the original, individually delivered LiFE in terms of reducing falls per physical activity. In this pilot study, we evaluate our conception of gLiFE for large-scale use in the subsequent, larger LiFE-is-LiFE trial.


Eligibility Criteria:
Inclusion Criteria:

* Community-dwelling
* Aged 70+

Exclusion Criteria:

* Cognitive impairment
* Neurological condition which severely influences gait and mobility
* Severe visual impairment
* Inability to ambulate independently
* Significant lung disease or chronic heart failure or any other unstable or terminal illness that would preclude the planned exercises
Ultrathin Bronchoscope and Radial Endobronchial Ultrasound (R-EBUS) With Fluoroscopy Versus Standard Fiberoptic Bronchoscopy (FB) (P00029233 )

The purpose of this study is to compare the yield of two methods for obtaining a lung tissue sample: Procedure #1: standard fiberoptic bronchoscopy (FB) with fluoroscopy, and Procedure #2: ultrathin bronchoscope procedure with fluoroscopy and radial endobronchial ultrasound (R-EBUS). These two procedures are similar in that they both: (1) enable your doctor to look inside your lungs with a device called a bronchoscope, and (2) Use fluoroscopy, which is a technique that uses X-rays to see your lungs.

This will give the doctor an opportunity to use either of the bronchoscopy methods described above and compare the tests to see if R-EBUS provides better results than standard bronchoscopy.


Eligibility Criteria:
Inclusion Criteria:

1. Patients with a solid lung lesion 2-5cm identified on chest CT with the intention to undergo bronchoscopic evaluation. If the lesion is partially solid (ie there is a ground glass component) then the solid portion must make up \>75% of the lesion and measure at 2-5cm.The decision to pursue biopsy will be made by the treating physician and agreed upon by the patient. This will include patients determined to have an intermediate risk of malignancy (5-65%) and those non-surgical candidate with higher risk lesions in need of diagnosis for alternative treatment. OR
2. Patients with a solid lung lesion 2-5cm identified on chest CT that are surgical candidates with a high probability of cancer (\>65%) will be referred for surgical evaluation. If the lesion is partially solid (ie there is a ground glass component) then the solid portion must make up \>75% of the lesion and measure at 2-5cm. If the patient refuses surgery or if the surgeon requests a definitive diagnosis prior to surgery the patient will have the option to be included in this study. All sites will use the same online calculator to document probability of malignancy.
3. Are at least 22 years old,
4. Lack Bleeding disorders, and
5. Are able to provide informed consent

Exclusion Criteria:

1. Patients with a pure ground-glass opacity identified on chest CT
2. Patients with endobronchial involvement seen on chest CT.
3. Patients who refuse to participate,
4. Are less than 22 years of age,
5. Lack fitness to undergo flexible bronchoscopy as determined by the bronchoscopist prior to procedure, and
6. Are unable to provide informed consent
7. Pregnant
Pulmonary Vein Isolation Outcomes With Fish Oils

Fish oil therapy may decrease the incidence of cardiac arrhythmias. This study will test whether pre-treatment with fish oils before catheter ablation of atrial fibrillation decreases the early post operative occurrence of atrial fibrillation.


Eligibility Criteria:
Inclusion Criteria:

* Paroxysmal Atrial fibrillation (PAF).
* Persistent atrial fibrillation. Persistent AF is not self-limited.

Exclusion Criteria:

* Previous pulmonary vein isolation ablation procedure
* Contraindication for anticoagulation
* Permanent AF
* Severe valvular pathology
* Concurrent use of antiarrhythmic medications
* Inability to give consent
* Pregnancy
PREventive Care Infrastructure Based On Ubiquitous Sensing (PRECIOUS). VHIR Pilot.

The goal of the MI field test is to assess users' overall satisfaction, usability and acceptability of the PRECIOUS system, and to explore if MI in combination with gamification principles is a feasible solution to foster adherence to PRECIOUS system. Moreover, it is pursued to trigger behavior change and build up motivation to maintain sustained change towards healthy lifestyles. The field test at University Hospital Vall d'Hebron will be carried out with morbidly obese pre-diabetic patients. This pilot test will serve to explore users' acceptance of PRECIOUS system in an early stage of its development. Considering that this is a pilot test, feedback and outcomes obtained will serve to refine and adjust PRECIOUS system concept and architecture.

The pilot test will recruit 30 morbidly obese pre-diabetic patient and they will be randomized into three groups: Group 1. Treatment as usual; Group 2. PRECIOUS system; Group 3. PRECIOUS system and Motivational Interviewing counseling. Researchers of this study will contact telephonically with potential participants and will ask for voluntary participation. Among those who agree, a face-to-face appointment at the reference hospital will be scheduled. In this appointment, general information on the study objectives and procedures will be offered.

The length of intervention will be 3 months with the following scheduled follow-up appointments: week 2 (considering baseline as week 1), week 5, week 8 and week 12. In the follow-up appointments 2, 5 and 8, only doubts and questions regarding system use will be addressed (not specific measures will be collected). Two types of measures will be assessed: 1) Primary outcome measures (at the end of the test) to assess usability, satisfaction, user's acceptance, and effectiveness of PRECIOUS system; and 2) Secondary outcome measures (baseline and final assessment) to assess different aspects of lifestyle and health habits. In addition, all patients will use a device to record heart rate during 3 consecutive days (week 1 and 12).

Eligibility Criteria:
Inclusion Criteria:

* All patients must be under the care of medical specialists who adheres to national guidelines for morbid obesity or pre-diabetic conditions.
* Age older than 18 years.
* Body max index (BMI): ≥ 30 mg/m2.
* Pre-diabetic condition following ADA criteria: fasting plasma glucose level from 5.6mmol/L (100 mg/dL) to 6.9mmol/L (125 mg/dL).
* Patients must be able to participate, understand and complete questionnaires in Spanish language.
* Patients must refer to be used to use multimedia platforms such as PDAs, tablets, laptops, smart phones or personal computers in a regular basis.

Exclusion Criteria:

* Any mental (e.g. cognitive impairment, severe psychopathology not stabilized) or physical condition that could interfere with the successful application of the research protocol.
* Patients will be recruited from specialist outpatient consultation at Vall d'Hebron Research Institute (VHIR). All patients must be under the care of specialists who adhere to national guidelines.
Living Conditions After Non-Hodgkin's Lymphoma in France

This is an innovative project, allowing to study for the first time the long-term living conditions of patients after diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL) from population data in France. Patients will be selected from the three specialized hematology registries in France: Côte-d'Or, Gironde and Basse-Normandie.

This is also one of the first studies to look at epidemiological indicators of net survival after diagnosis of follicular lymphoma and diffuse large B-cell lymphoma, adjusted for clinical factors such as disease stage, therapeutic management, and comorbidities, apart from the standard adjustment factors of age, sex, and time of diagnosis in real life. In addition, the proportion of cured patients will be estimated.

For component 1, this will be the survival analysis on the initial data. For part 2, questionnaires will be sent out followed by a follow-up if necessary one month after the mailing. There is no physical interview nor any specific biological or imaging examination.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis period 2010-2018, according to the 2008 WHO ICD-O-3 classification, from the hematological malignancy registries of Côte-d'Or, Gironde, Basse-Normandie
* Patients with a diagnosis of follicular lymphoma (9690/3, 9691/3, 9695/3, 9698/3, 9597/3)
* Patients with a diagnosis of diffuse large B-cell lymphoma (9678/3, 9679/3, 9680/3, 9684/3, 9688/3, 9712/3, 9735/3, 9737/3, 9738/3)
* For Part 2: Individuals alive at the date of vital status update

Non-inclusion criteria:

* Other forms of malignant hemopathies at diagnosis,
* Minors.

Exclusion Criteria:

* Person under a legal protection measure (curatorship, guardianship)
* Person under a legal protection measure (guardianship, tutorship)
* Pregnant, parturient or breastfeeding women
* Major incapable or unable to express his consent
* Person who did not return the questionnaires following the 1-month follow-up, or patient who expressed refusal to participate.
Impact of the PIKSEC App on Intravenous Insertion Success, Pain, and Emotional Manifestation in Pediatric Patients: a Non-Randomized Controlled Trial

The study employed a post-test non-randomized controlled trial to assess the impact of the PİKSEÇ (Peripheral Intravenous Catheter Selection) application on the success of peripheral intravenous catheter (PIVC) placement, as well as on the pain and emotional level scores of hospitalized preschool children aged 3-6 years. In preschool children, aged 3-6 years, who were hospitalized, anxiety about losing body integrity is commonly observed. Children tend to think that all the material inside their bodies can come out through a wound or hole during invasive procedures. Therefore, it becomes crucial to reduce anxiety related to invasive procedures in children of this age group. In this context, the study aimed to be conducted in preschool children.


Eligibility Criteria:
Inclusion Criteria:

* Being a child in the 3-6 age group
* PIVC to be inserted
* Parents volunteering their child to participate in the study and signing the consent form
* Parents are literate

Exclusion Criteria:

* Physical and mental disabilities,
* The parent has an obstacle to communication (being mentally stable, etc.)
Predicting Transfers to Hemodialysis in Peritoneal Dialysis Patients Using the Surprise Question

The investigators will assess the prediction performance of the modified Surprise Question (Will the participant be surprised if this patient transfers to hemodialysis in the next 6 months?) for identification of peritoneal dialysis at high risk of transfer to hemodialysis. The investigators will also assess the prediction performance of a modified mortality surprise question (Will the participant be surprised if this patient dies in the next 6 months?).

Physicians and nurses will be asked two questions regarding each of their peritoneal dialysis patients:

1. Will the participant be surprised if this patient transfers to hemodialysis in the next 6 months?
2. Will the participant be surprised if this patient dies in the next 6 months?

Patients will be followed for 6 months for outcomes (with two extra months for ascertainment of outcomes).

Eligibility Criteria:
Patients:

Inclusion Criteria:

* Incident and prevalent PD population at Satellite Healthcare

Exclusion Criteria:

* Age \< 18 years
* Patients already enrolled in hospice
* Patients on PD training
* Patients on backup hemodialysis
Elecsys HE4 Chinese Reference Value Study

Aim of this study is to provide specimens for establishing reference values of HE4 in an apparently healthy Chinese population using the Roche Elecsys HE4 assay tested on variety of Elecsys and cobas brand immunoassay analyzers. This reference range will be compared to population of subjects who have signs and symptoms of various benign and malignant diseases, including ovarian cancer. This reference range will also be compared to the levels of HE4 in individual subjects who have been diagnosed with ovarian cancer and are being followed longitudinally for recurrence or progression of their disease.


Eligibility Criteria:
Inclusion Criteria (all cohorts):

* appropriate clinical data
* normal appearance of sample
* minimum 0.5 ml volume available

Exclusion Criteria (all cohorts):

* \< 18 years of age
* insufficient volume
* insufficient clinical information
* \> 3 freeze/thaw cycles of samples
* Stored or shipped at \> 0°C
* Icteric, lipemic, hemolytic, substantial particulates
Smoke-free Home Study in Subsidized Housing

Comprehensive smoke-free policies have the potential to substantially reduce tobacco-related disparities among populations in subsidized housing. This study fills this gap by identifying approaches to increase the implementation of smoke-free policies in all types of subsidized housing by increasing the voluntary adoption of smoke-free homes and promoting access to smoking cessation services.

OBJECTIVES:

The investigators will build on previous studies, where a smoke-free home intervention to increase voluntary adoption of smoke-free homes in permanent supportive housing for formerly homeless adults was developed and evaluated.

Aim 1: To estimate the effect of our adapted smoke-free home intervention on the primary outcome of residents' voluntary adoption of smoke-free homes and the secondary outcome of biochemically-verified tobacco abstinence at 6-months follow-up.

Aim 2: To determine the cost of our adapted smoke-free home intervention and determine whether it is a cost-effective use of health care resources.

Aim 3: To evaluate variation in stakeholders' perspectives on the adapted smoke-free home intervention's adaptability, scalability and sustainability.The proposed intervention can expand access to smoke-free policies and smoking cessation services in subsidized housing, thereby reducing racial/ethnic disparities in tobacco use, tobacco exposure and chronic disease in these populations.

OUTLINE:

A wait-list cluster randomized controlled trial of the adapted smoke-free home intervention compared to usual care among residents from subsidized housing sites in Northern California. Participants from twenty-four subsidized housing sites will be randomized into intervention and waitlist control arms

Eligibility Criteria:
Inclusion Criteria:

Eligible resident participants

* Current smokers defined as:

  * Smoked at least 100 cigarettes in lifetime
  * Smoked daily in the past 7 days, and at least 5 cigarettes per day, verified by expired CO ≥ 5 parts per million \[ppm\] Smokerlyzer CO+ monitor),
  * Smoke in their home
* Expect to live in the subsidized housing site for at least 12 months
* Age ≥ 18 years
* Speak Chinese (Cantonese or Mandarin), English, Spanish, or Vietnamese
* Able to provide informed consent.

Exclusion Criteria:

* Contraindication to any study-related procedures or assessment
Impact of Transfusional Practice on the Morbidity and Mortality of Patients in Intensive Care Unit

This study will allow correlating transfusion monitoring and patients' prognostic according to the chosen outcome criteria.

These data could thus represent a basis for transfusion recommendations, except for intensive care and vital emergencies.

It will also bring information about the actual transfusion monitoring in intensive care unit (ICU), in the period following the stay in the ICU and after hospital discharge.


Eligibility Criteria:
Inclusion criteria:

* Patient admitted to medical and surgical resuscitation units of Besançon and Dijon university hospitals, all causes considered
* Patient admitted between 1st January 2012 to 31st December 2017